BUSINESS

Daiichi Sankyo, Tokyo Institute of Technology Launch Open Innovation Research for Type 1 Diabetes Treatment Using iPS Cells

January 11, 2019
Daiichi Sankyo, Mitsubishi UFJ Capital, and the Tokyo Institute of Technology said on January 10 that they will commence open innovation research with the aim of developing an innovative therapy for severe type 1 diabetes based on a technique to…

To read the full story

BUSINESS

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…